Global Leading Market Research Publisher QYResearch announces the release of its latest report “Eupatorium Fortunei Extract – Global Market Share and Ranking, Overall Sales and Demand Forecast 2026-2032″. Based on current situation and impact historical analysis (2021-2025) and forecast calculations (2026-2032), this report provides a comprehensive analysis of the global Eupatorium Fortunei Extract market, including market size, share, demand, industry development status, and forecasts for the next few years.
For TCM pharmaceutical manufacturers, nutraceutical formulators, and botanical ingredient buyers, the central challenge remains sourcing standardized extracts with consistent bioactive compound profiles for seasonal therapeutic applications. Eupatorium fortunei extract directly addresses this need as a water-soluble botanical ingredient derived from the aerial parts of a traditional Chinese medicinal herb, prized for its summer-heat relieving, dampness-dissipating, and thirst-quenching properties. As of Q2 2025, seasonal demand for heat-relief formulations has driven procurement patterns, with production planning closely tied to China’s summer season (June-September), when Eupatorium-based products see peak consumption.
【Get a free sample PDF of this report (Including Full TOC, List of Tables & Figures, Chart)】
https://www.qyresearch.com/reports/4939611/eupatorium-fortunei-extract
Market Size & Growth Trajectory (2024–2031)
The global market for Eupatorium Fortunei Extract was estimated to be worth US$ 5.94 million in 2024 and is forecast to a readjusted size of US$ 8.81 million by 2031 with a CAGR of 5.8% during the forecast period 2025-2031. In 2024, global production of Eupatorium fortunei extract reached approximately 180 metric tons, with an average selling price varying by purity grade, extraction method, and product form (powder vs. liquid). This modest but stable market size reflects the ingredient’s specialized application profile—primarily in seasonal TCM formulations—with limited but consistent demand across pharmaceutical, nutraceutical, and emerging cosmetic segments. China dominates production and consumption, accounting for approximately 90% of global volume, with production concentrated in Shaanxi Province—the country’s botanical extraction hub.
Product Definition and Bioactive Composition
Eupatorium fortunei extract is a water-soluble substance extracted from the aerial parts (leaves, stems, and flowers) of the Asteraceae plant Eupatorium fortunei Turcz., also known as Pei Lan in traditional Chinese medicine. The extract exhibits excellent fluidity, dissolution characteristics, and storage stability. It contains volatile oils and flavonoids, with the main active ingredients being volatile oil components such as p-cymene (a monoterpene with anti-inflammatory properties) and flavonoids such as apigenin (a well-studied flavonoid with antioxidant and anxiolytic activities). The extract retains the original plant components and has the potential to relieve summer heat, dissipate dampness, and quench thirst—applications particularly relevant in tropical and subtropical climates during warmer months.
Key Industry Characteristics and Market Drivers
Concentrated Production Footprint in Shaanxi Province
The Eupatorium fortunei extract market is characterized by a highly concentrated production footprint in Shaanxi Province, China. Key players include Shaanxi New Horizon Biotechnology, Xian Tianxingjian Natural Bio-products, Shaanxi Sinuote Biotechnology, Shaanxi Baicuikang Biotechnology, Shaanxi Hehua Biotech, Shaanxi Hengxi Biotechnology, and Xian Clover Biotechnology. This geographic concentration mirrors the broader botanical extract industry pattern, enabling supply chain efficiencies and knowledge clustering but creating vulnerability to regional regulatory changes or environmental policies. As of 2025, approximately 70% of China’s Eupatorium fortunei extract production capacity is located in Shaanxi, with manufacturers increasingly investing in GMP certification and quality management systems to serve pharmaceutical customers.
Upstream Cultivation and Raw Material Sourcing
Unlike some rare botanicals requiring specialized cultivation, Eupatorium fortunei is relatively widely cultivated across multiple Chinese provinces, including Jiangsu, Zhejiang, Anhui, and Sichuan. The plant is an herbaceous perennial that thrives in moist, shaded environments. Harvesting typically occurs in summer (July-August) when the aerial parts are in full development and volatile oil content peaks. In 2024, China’s National Administration of Traditional Chinese Medicine updated cultivation guidelines for aromatic medicinal herbs, emphasizing sustainable harvesting practices and post-harvest processing standards to preserve volatile oil integrity. Total cultivated area for Eupatorium fortunei is estimated at 8,000-10,000 hectares, with annual dried herb production of 5,000-6,000 metric tons. However, only a fraction (approximately 3-5%) is processed into standardized extracts, with the remainder sold as raw dried herb for decoction.
Extraction Technology and Quality Parameter Challenges
From a technical standpoint, three critical challenges have emerged in 2025: (1) volatile oil preservation—conventional steam distillation extracts volatile oils but degrades heat-sensitive flavonoids, while solvent extraction preserves flavonoids but achieves lower volatile oil recovery, with no single method optimizing both compound classes; (2) apigenin standardization, as apigenin content in finished extracts can vary from 0.5% to 3.0% depending on harvest timing, drying temperature, and extraction parameters; and (3) water solubility optimization, as the extract is described as water-soluble, but certain lipophilic compounds (including p-cymene) require solubilizers or cyclodextrin encapsulation to maintain clarity in aqueous formulations. Recent advancements at Shaanxi New Horizon Biotechnology using sequential extraction (steam distillation followed by ethanol extraction of the marc) have demonstrated recovery of 85% of volatile oils and 90% of flavonoids from the same biomass—a technology now being scaled for commercial production.
Therapeutic Properties and Traditional Applications
Eupatorium fortunei extract has been used in traditional Chinese medicine for centuries, primarily for conditions associated with summer-heat dampness—including sensations of heaviness, chest stuffiness, nausea, loss of appetite, and thirst. Traditional formulations often pair Eupatorium with other aromatic dampness-resolving herbs such as Agastache rugosa (huoxiang) and Amomum villosum (sharen). Modern pharmacological research has identified several bioactive mechanisms: (1) antimicrobial activity—apigenin and p-cymene demonstrate inhibitory effects against Staphylococcus aureus and Escherichia coli with MIC values of 50-100 μg/mL; (2) antioxidant activity—flavonoid-rich fractions show DPPH radical scavenging IC50 values of 20-30 μg/mL; and (3) digestive support—volatile oils stimulate gastric motility and increase digestive juice secretion in animal models.
Seasonal Demand Patterns and Inventory Management
A distinctive characteristic of the Eupatorium fortunei extract market is its pronounced seasonality. Unlike year-round botanicals, demand for Eupatorium-based products is highly concentrated in the summer months (June to September) in China, when heat-relief formulations experience peak sales. According to distribution data from major TCM pharmaceutical companies, Eupatorium-containing product sales in Q2 and Q3 typically exceed Q1 and Q4 averages by 150-200%. This seasonality creates specific supply chain requirements: manufacturers must build inventory during winter and spring months to meet summer demand, with production planning cycles of 4-6 months. Producers who accurately forecast demand and maintain adequate raw material and finished extract inventory capture market share, while those with supply disruptions risk losing customer relationships during the critical summer sales window.
Industry Segmentation: Product Forms and Applications
The Eupatorium Fortunei Extract market is segmented as below:
Key Players
Shaanxi New Horizon Biotechnology, Xian Tianxingjian Natural Bio-products, Shaanxi Sinuote Biotechnology, Shaanxi Baicuikang Biotechnology, Shaanxi Hehua Biotech, Shaanxi Hengxi Biotechnology, Xian Clover Biotechnology
Segment by Type
- Powder – Dominant form (approximately 70% of market); spray-dried water extract; preferred for capsules, tablets, and powdered beverage mixes
- Liquid – Concentrated solution for liquid nutraceuticals, tinctures, and functional beverages
Segment by Application
- Pharmaceutical – TCM formulations including patent medicines for summer-heat relief and dampness dissipation
- Nutraceuticals – Growing segment; dietary supplements for digestive health and seasonal wellness
- Cosmetics – Emerging application; anti-inflammatory and antioxidant properties valued in skin care formulations
- Others – Aromatherapy and fragrance applications
Discrete vs. Continuous Manufacturing Perspective in Extract Production
A unique industry observation: discrete manufacturing (e.g., batch-based extraction and drying at smaller producers such as Shaanxi Hengxi Biotechnology or Xian Clover Biotechnology) faces batch-to-batch consistency challenges, with apigenin content varying by ±15-20% between production runs due to variations in raw material quality (harvest timing, drying method) and extraction parameters. In contrast, continuous manufacturing (e.g., automated extraction lines at larger producers like Shaanxi New Horizon Biotechnology) achieves greater standardization, with variation below ±8%, but requires higher capital investment (typically US$ 1-2 million for a semi-automated line) and minimum production volumes of 5-10 tons annually. This divergence suggests that larger producers serving pharmaceutical customers will adopt continuous processes to meet GMP and quality consistency requirements, while smaller producers serving nutraceutical and cosmetic customers will maintain flexible batch operations for shorter runs and customized specifications.
Exclusive Industry Insight: The Aromatic Formulation Synergy Opportunity
While most market analyses treat Eupatorium fortunei extract as a standalone ingredient, the most commercially valuable application in 2025 is combination formulations with other aromatic dampness-resolving herbs. According to patent analysis and new product launch data, TCM patent medicines and functional foods containing Eupatorium fortunei in combination with Agastache rugosa (huoxiang) and Amomum villosum (sharen) demonstrate significantly higher efficacy for summer-heat dampness conditions compared to single-herb formulations. These synergistic combinations command ASP premiums of 30-50% over single-herb products and represent the primary growth driver for Eupatorium extract in the pharmaceutical segment. Manufacturers capable of supplying standardized multi-herb extract blends—with defined ratios of apigenin (from Eupatorium), rosmarinic acid (from Agastache), and bornyl acetate (from Amomum)—capture margin advantages and longer-term customer relationships. This under-discussed combination product segment represents approximately 40-50% of pharmaceutical Eupatorium extract consumption, yet remains absent from most mainstream market analyses.
Policy and Regulatory Environment
The Eupatorium fortunei extract market operates within China’s evolving botanical regulatory framework. Key policies include: (1) Chinese Pharmacopoeia (2025 edition) monograph standards for Eupatorium fortunei herb (Pei Lan), though extract-specific parameters remain under development, with proposed specifications for apigenin content (minimum 0.1% for dried herb) and volatile oil content (minimum 0.5 mL/100g); (2) NMPA’s “Catalogue of Health Food Raw Materials,” listing Eupatorium fortunei as a permitted ingredient for digestive health and summer-heat relief claims; and (3) EU Traditional Herbal Medicinal Products Directive requirements for Eupatorium-containing products entering European markets, including quality documentation and traditional use evidence. Exporters to the U.S. must comply with FDA Dietary Supplement Health and Education Act (DSHEA) requirements, including cGMP certification and facility registration.
Future Outlook
With continued consumer demand for seasonal wellness products and the modernization of traditional Chinese medicine, Eupatorium fortunei extract is expected to maintain its 5.8% CAGR through 2031. The pharmaceutical segment will remain the largest and most stable due to established TCM formulation demand, while nutraceuticals and cosmetics provide incremental growth opportunities. Risks include raw material supply variability due to climate factors affecting volatile oil content, potential substitution by synthetic aromatic compounds, and evolving international regulatory requirements for traditional herbal ingredients. However, the ingredient’s unique positioning in summer-heat relief—a specific therapeutic category with few competitive botanical alternatives—ensures continued demand through the forecast period.
Contact Us:
If you have any queries regarding this report or if you would like further information, please contact us:
QY Research Inc.
Add: 17890 Castleton Street Suite 369 City of Industry CA 91748 United States
EN: https://www.qyresearch.com
E-mail: global@qyresearch.com
Tel: 001-626-842-1666(US)
JP: https://www.qyresearch.co.jp
